Literature DB >> 16249431

The human glomerular podocyte is a novel target for insulin action.

Richard J M Coward1, Gavin I Welsh, Jing Yang, Candida Tasman, Rachel Lennon, Ania Koziell, Simon Satchell, Geoffrey D Holman, Dontscho Kerjaschki, Jeremy M Tavaré, Peter W Mathieson, Moin A Saleem.   

Abstract

Microalbuminuria is significant both as the earliest stage of diabetic nephropathy and as an independent cardiovascular risk factor in nondiabetic subjects, in whom it is associated with insulin resistance. The link between disorders of cellular insulin metabolism and albuminuria has been elusive. Here, we report using novel conditionally immortalized human podocytes in vitro and human glomeruli ex vivo that the podocyte, the principal cell responsible for prevention of urinary protein loss, is insulin responsive and able to approximately double its glucose uptake within 15 min of insulin stimulation. Conditionally immortalized human glomerular endothelial cells do not respond to insulin, suggesting that insulin has a specific effect on the podocyte in the glomerular filtration barrier. The insulin response of the podocyte occurs via the facilitative glucose transporters GLUT1 and GLUT4, and this process is dependent on the filamentous actin cytoskeleton. Insulin responsiveness in this key structural component of the glomerular filtration barrier may have central relevance for understanding of diabetic nephropathy and for the association of albuminuria with states of insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16249431     DOI: 10.2337/diabetes.54.11.3095

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  97 in total

Review 1.  The podocyte cytoskeleton--key to a functioning glomerulus in health and disease.

Authors:  Gavin I Welsh; Moin A Saleem
Journal:  Nat Rev Nephrol       Date:  2011-10-25       Impact factor: 28.314

2.  Translationally controlled tumour protein is associated with podocyte hypertrophy in a mouse model of type 1 diabetes.

Authors:  D K Kim; B Y Nam; J J Li; J T Park; S H Lee; D H Kim; J Y Kim; H Y Kang; S H Han; T H Yoo; D S Han; S W Kang
Journal:  Diabetologia       Date:  2012-02-04       Impact factor: 10.122

Review 3.  Signal transduction in podocytes--spotlight on receptor tyrosine kinases.

Authors:  Jochen Reiser; Sanja Sever; Christian Faul
Journal:  Nat Rev Nephrol       Date:  2014-01-07       Impact factor: 28.314

Review 4.  Resistance to insulin and kidney disease in the cardiorenal metabolic syndrome; role for angiotensin II.

Authors:  Ravi Nistala; Adam Whaley-Connell
Journal:  Mol Cell Endocrinol       Date:  2013-02-15       Impact factor: 4.102

Review 5.  Shiga toxin pathogenesis: kidney complications and renal failure.

Authors:  Tom G Obrig; Diana Karpman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 6.  Mechanisms of Synergistic Interactions of Diabetes and Hypertension in Chronic Kidney Disease: Role of Mitochondrial Dysfunction and ER Stress.

Authors:  Zhen Wang; Jussara M do Carmo; Alexandre A da Silva; Yiling Fu; John E Hall
Journal:  Curr Hypertens Rep       Date:  2020-02-03       Impact factor: 5.369

Review 7.  The impact of insulin resistance on the kidney and vasculature.

Authors:  Ferruh Artunc; Erwin Schleicher; Cora Weigert; Andreas Fritsche; Norbert Stefan; Hans-Ulrich Häring
Journal:  Nat Rev Nephrol       Date:  2016-10-17       Impact factor: 28.314

Review 8.  Redox control of renal function and hypertension.

Authors:  Ravi Nistala; Adam Whaley-Connell; James R Sowers
Journal:  Antioxid Redox Signal       Date:  2008-12       Impact factor: 8.401

Review 9.  Minimal change nephropathy and focal segmental glomerulosclerosis.

Authors:  Peter W Mathieson
Journal:  Semin Immunopathol       Date:  2007-10-23       Impact factor: 9.623

10.  An initial evaluation of post-cardiopulmonary bypass acute kidney injury in swine.

Authors:  Gavin J Murphy; Hua Lin; Richard J Coward; Tibor Toth; Robin Holmes; David Hall; Gianni D Angelini
Journal:  Eur J Cardiothorac Surg       Date:  2009-08-18       Impact factor: 4.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.